Vanda Pharmaceuticals Reports First Quarter 2026 Financial Results
Vanda Pharmaceuticals reported Q1 2026 total net product sales of $51.7 million, a 3% increase year-over-year, driven by a 26% surge in Fanapt sales to $29.6 million. The company raised its full-year 2026 revenue guidance to $240-$290 million from $230-$260 million to include the newly launched NEREUS product, which is available via a direct-to-consumer platform.
Key figures
- Revenue
- 51718000
- Guidance
- Full Year 2026 total revenue $240 to $290 million, raised from $230 to $260 million
- Revenue Yoy
- 3%
- Cash burn
- 61500000
- Fanapt sales
- 29600000
- Cash position
- 202300000
- Hetlioz sales
- 15947000
- Ponvory sales
- 6211000
- Fanapt sales yoy
- 26%
- Neresus guidance
- $10 to $30 million
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.